These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28271563)

  • 1. Gastric cancer management: Kinases as a target therapy.
    Farran B; Müller S; Montenegro RC
    Clin Exp Pharmacol Physiol; 2017 Jun; 44(6):613-622. PubMed ID: 28271563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New targeted therapies for gastric cancer.
    Asaoka Y; Ikenoue T; Koike K
    Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging kinase inhibitors of the treatment of gastric cancer.
    Vincenzi B; Imperatori M; Silletta M; Marrucci E; Santini D; Tonini G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):479-93. PubMed ID: 26021342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification.
    Lee J; Ou SH
    Discov Med; 2013 Jun; 15(85):333-41. PubMed ID: 23819947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
    Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
    Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting receptor tyrosine kinases in gastric cancer.
    Morishita A; Gong J; Masaki T
    World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
    Ayyappan S; Prabhakar D; Sharma N
    Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 testing in gastric cancer: An update.
    Abrahao-Machado LF; Scapulatempo-Neto C
    World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in gastric cancer and future perspectives.
    Yazici O; Sendur MA; Ozdemir N; Aksoy S
    World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
    Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
    Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeted therapy for the treatment of gastric cancer.
    Xu W; Yang Z; Lu N
    J Exp Clin Cancer Res; 2016 Jan; 35():1. PubMed ID: 26728266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.
    Hong L; Han Y; Liu J; Brain L
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):759-65. PubMed ID: 24134151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted therapies in advanced gastric cancer.
    Janjigian YY; Shah MA
    Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
    Corso S; Giordano S
    Trends Mol Med; 2016 Jul; 22(7):534-544. PubMed ID: 27260398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cMET as a potential therapeutic target in gastric cancer (Review).
    Teng L; Lu J
    Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances of Molecular Targeted Therapy in Gastric Cancer.
    Cetin B; Gumusay O; Cengiz M; Ozet A
    J Gastrointest Cancer; 2016 Jun; 47(2):125-34. PubMed ID: 26875080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in gastroesophageal cancer.
    Kasper S; Schuler M
    Eur J Cancer; 2014 May; 50(7):1247-58. PubMed ID: 24495747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.